Zealand Pharma Announces Boehringer Ingelheim's Survodutide Phase III Trial Showed Targeted Fat Reduction in Obesity and MASLD

Survodutide Phase III Trials Show Significant Fat Reduction in Obesity and MASLD

Zealand Pharma announced positive Phase III results for Boehringer Ingelheim's survodutide, a glucagon/GLP-1 dual agonist, from two global trials: SYNCHRONIZE-1 for obesity and SYNCHRONIZE-MASLD for metabolic dysfunction-associated steatotic liver disease (MASLD) with obesity/overweight. SYNCHRONIZE-1 showed up to 16.6% weight loss, with targeted reductions of up to 34% in visceral fat and 63.1% in liver fat over 76 weeks, minimizing lean mass loss. SYNCHRONIZE-MASLD demonstrated up to 84.2% of participants achieving at least 30% relative liver fat reduction and up to 12.2% body weight reduction over 48 weeks, with 61% reaching liver fat normalization. These results were presented at the ADA 2026 Scientific Sessions and published in The New England Journal of Medicine and Nature Medicine. Zealand Pharma is eligible for royalties and EUR 315 million in potential milestone payments.

• The 76-week Phase III SYNCHRONIZE-1 trial in adults with obesity or overweight without type 2 diabetes demonstrated significant efficacy. Participants achieved up to an average of 16.6% body weight loss, a statistically significant decrease compared to placebo (p<0.0001). A sub-study further revealed targeted reductions of up to 34.0% in visceral fat and 63.1% in liver fat, with lean mass loss accounting for no more than 10.8% of total tissue mass change, indicating primary fat reduction.
• The 48-week Phase III SYNCHRONIZE-MASLD trial in adults with obesity/overweight and MASLD met its co-primary endpoints. Up to 84.2% of participants treated with survodutide achieved at least a 30% relative liver fat reduction (p<0.0001), alongside up to 12.2% body weight reduction (p<0.0001). Notably, 61.0% of patients reached liver fat normalization (liver fat content <5%) at Week 48, highlighting survodutide's potential to improve metabolic health beyond just weight loss.
• Survodutide, a glucagon/GLP-1 dual agonist, leverages both mechanisms to decrease appetite and increase satiety (GLP-1 agonism) while directly acting on the liver to reduce hepatic fat, regulate metabolic function, and resolve inflammation (glucagon agonism). This differentiated approach is being further explored in an expanded Phase IIIb program, including studies for women's health (SYNCHRONIZE-HERA) and cardiac function (ELEVATE-LIVER), complementing its existing regulatory designations like FDA Fast Track and Breakthrough Therapy.

Survodutide's Impact on Visceral Fat, Liver Fat, and Weight Loss

Recent clinical studies have demonstrated significant advances in obesity treatment, with next-generation pharmacological interventions showing unprecedented efficacy. Tirzepatide and novel multi-receptor agonists are emerging as transformative therapies, achieving weight reductions comparable to bariatric surgery while maintaining favorable safety profiles.

• Tirzepatide Systematic Review (2025): Nine RCTs with 7,111 participants comparing tirzepatide (5-15 mg weekly) to placebo showed medium-term weight reduction of -16.03% (95% CI -18.91 to -13.14) with 3.6-fold higher likelihood of achieving ≥5% weight loss, though increased non-serious adverse events (RR 1.33) and withdrawal rates (RR 2.06)

• Liraglutide Meta-Analysis (2025): Twenty-four RCTs involving 9,937 participants demonstrated medium-term weight reduction of -4.72% (95% CI -5.32 to -4.12) and 2.1-fold increased probability of ≥5% weight loss, with elevated adverse event withdrawal rates (RR 1.98) but no significant difference in serious adverse events or mortality

• Mazdutide Phase 3 Trial (2026): Chinese adults with obesity receiving mazdutide 9 mg achieved -12.78% weight loss versus 1.80% with placebo at 24 weeks, with 81.7% achieving ≥5% weight reduction but high rates of gastrointestinal adverse events including nausea (50.0%), diarrhea (38.3%), and vomiting (36.7%)

• Multi-Receptor Agonist Network Meta-Analysis (2026): Fourteen RCTs comparing novel agents showed retatrutide achieving greatest weight reduction (-13.44 kg; 95% CI -18.38 to -8.51) followed by survodutide (-10.74 kg), while mazdutide demonstrated the most favorable tolerability profile among evaluated agents

• Oral Semaglutide OASIS-4 Trial (2025): Semaglutide 25 mg daily achieved 13.6% mean weight loss over 64 weeks with 63% of participants achieving ≥10% weight loss, though associated with gastrointestinal adverse events consistent with GLP-1 receptor agonist class and mild dysesthesia

Survodutide's Dual Agonism: Beyond Weight Loss for Metabolic Health

Current obesity treatment approaches face several interconnected challenges that limit their effectiveness and accessibility. The most pressing issues include determining appropriate prescribing authority and management protocols for obesity pharmacotherapy, as well as the necessity for lifelong treatment to sustain therapeutic benefits from these medications. Reimbursement barriers across Medicaid, Medicare, and commercial insurance plans create significant access limitations, while drug shortages compounded by high demand and direct-to-consumer marketing have introduced additional safety and ethical concerns around compounded formulations.

Despite recent advances with GLP-1-based agents demonstrating substantial weight reduction, the fundamental challenge of treatment durability persists, as patients require ongoing therapy to maintain outcomes. The current stepwise treatment algorithm, which typically begins with lifestyle interventions followed by pharmacotherapy and reserves bariatric surgery as a last resort, often proves insufficient in terms of efficacy, tolerability, and safety. While lifestyle modifications remain first-line treatment, the high risk of relapse has intensified focus on pharmacotherapeutic interventions, yet relatively few patients access the most effective currently available treatment of bariatric surgery.

The field faces a critical gap between patient expectations and treatment outcomes, with current pharmacological options demonstrating only modest efficacy or requiring high doses with unacceptable side effects. The ultimate goal of matching bariatric surgery's efficacy through combination medicines remains elusive, though emerging dual and triple incretin agonists show promise. Effective obesity management requires a coordinated, multidisciplinary approach that addresses not only the limited therapeutic options for early diagnosis and long-term management, but also the need for population-based strategies involving conceptual shifts toward community- and environment-focused interventions supported by equitable insurance coverage and enhanced regulatory oversight.

Unpacking SYNCHRONIZE-1 and SYNCHRONIZE-MASLD Trial Designs

The major obesity clinical trials have employed diverse study designs ranging from randomized controlled trials to systematic reviews, with sample sizes varying from small pilot studies of fewer than 100 participants to large-scale trials enrolling thousands of patients. These studies have consistently focused on weight-related endpoints, with BMI reduction serving as the primary outcome measure across most trials.

Expanding Survodutide's Potential in MASH and Beyond

Beyond obesity, survodutide is being investigated across multiple metabolic and cardiovascular indications, reflecting its potential as a dual glucagon/GLP-1 receptor agonist. Clinical trials span from Phase II through Phase III studies, employing various intervention models tailored to specific patient populations and therapeutic objectives.

• Type 2 Diabetes: Phase II multicentre, randomised, double-blind, placebo-controlled trial in participants aged 18-75 years with HbA1c levels of 53-86 mmol/mol (7.0-10.0%) and BMI of 25-50 kg/m² on metformin background therapy, with randomisation to survodutide doses up to 0.3-2.7 mg once weekly or 1.2-1.8 mg twice weekly versus placebo or open-label semaglutide

• Type 2 Diabetes with Obesity (SYNCHRONIZE-2): Phase III double-blind trial enrolling 755 participants with baseline BMI ≥27 kg/m² and T2D, randomised to once-weekly subcutaneous survodutide (uptitrated to 3.6 or 6.0 mg with dose flexibility) or placebo, both added to lifestyle modification over 76 weeks

• Metabolic Dysfunction-Associated Steatohepatitis (MASH): 48-week Phase II trial in adults with biopsy-confirmed MASH and fibrosis stages F1-F3, using 1:1:1:1 randomisation to once-weekly subcutaneous survodutide at 2.4, 4.8, or 6.0 mg versus placebo, with 24-week dose-escalation followed by 24-week maintenance phases

• MASH-Cirrhosis: Ongoing Phase III trials in compensated MASH cirrhosis patients with clinically significant portal hypertension, Child-Turcotte-Pugh A cirrhosis, and magnetic resonance elastography >6.5 kPa, designed as event-driven studies with 3-5 years follow-up targeting major adverse liver outcomes

• Cardiovascular Outcomes (SYNCHRONIZE-CVOT): Phase III randomised, double-blind, event-driven cardiovascular safety study targeting 4,935 adults with BMI ≥27 kg/m² and established cardiovascular disease or chronic kidney disease, comparing once-weekly subcutaneous survodutide versus placebo with primary endpoint of 5-point major adverse cardiovascular events

Survodutide's Dual Impact: Reshaping Obesity and MASLD Treatment

The recent Phase III data for survodutide marks a pivotal moment in the treatment of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). As a dual glucagon/GLP-1 receptor agonist, survodutide leverages a synergistic mechanism that appears to drive superior metabolic outcomes compared to single-target GLP-1 receptor agonists. The reported weight loss of up to 16.6% is highly competitive, but the targeted reductions in visceral fat (up to 34%) and liver fat (up to 63.1%), alongside the crucial preservation of lean muscle mass, truly differentiate this agent. This body composition benefit is particularly significant, as it addresses key drivers of metabolic disease progression.

For MASLD, the results are equally compelling, with a high proportion of patients achieving substantial liver fat reduction and even normalization. This positions survodutide as a potential game-changer for a condition with limited effective pharmacological options, especially considering its potential for use in patients with cirrhosis, as suggested by earlier studies. The strategic implications are clear: survodutide is poised to be a formidable contender in both the rapidly expanding anti-obesity and MASLD markets, offering a comprehensive metabolic solution.

However, the path forward is not without its challenges. As with all potent metabolic therapies, tolerability, particularly gastrointestinal adverse events, will be a key factor influencing patient adherence and real-world outcomes. Furthermore, while the metabolic benefits are robust, long-term safety data and definitive cardiovascular outcomes are still being gathered, which will be crucial for broad adoption and payer acceptance. The competitive landscape is also intensifying, with a growing pipeline of dual and triple agonists. Securing favorable market access and reimbursement will require a strong value proposition that highlights survodutide's unique benefits in body composition and liver health, justifying its likely premium pricing amidst increasing budget scrutiny.